600285 羚锐制药
2021/03 - 三个月2020/122019/122018/122017/12

盈利能力分析
净资产收益率 ROE (%)4.07914.39413.72011.43010.190
总资产报酬率 ROA (%)2.6729.6119.1647.5816.904
投入资产回报率 ROIC (%)3.80913.57112.5979.9648.803

边际利润分析
销售毛利率 (%)77.60176.90877.28776.06973.125
营业利润率 (%)19.15715.74415.82914.34314.419
息税前利润/营业总收入 (%)18.55214.96515.72414.16514.838
净利润/营业总收入 (%)16.38613.91313.59011.97012.168

收益指标分析
经营活动净收益/利润总额(%)97.13591.64698.35798.34789.735
价值变动净收益/利润总额(%)-0.35811.300-2.929-4.5236.799
营业外收支净额/利润总额(%)0.045-0.794-0.048-3.922-1.073

偿债能力分析
流动比率 (X)1.7491.7971.7301.6921.602
速动比率 (X)1.4811.4871.4481.3481.240
资产负债率 (%)35.48932.84233.03432.65333.363
带息债务/全部投入资本 (%)5.1911.7923.3726.43812.048
股东权益/带息债务 (%)1,764.3655,320.4492,763.6361,404.117699.651
股东权益/负债合计 (%)181.075203.656201.755205.038197.034
利息保障倍数 (X)-30.235-22.819-161.17138.92525.946

营运能力分析
应收账款周转天数 (天)24.56924.56829.97435.44124.072
存货周转天数 (天)227.513206.642224.293252.375307.658